Bionomics is developing BNC105 but will not market the drug. Instead, it is searching for other pharmaceutical companies to take BNC105's development further.
-
BNC105 is in a new class of treatments that disrupt blood supply to cancerous... -
Phase II clinical trials are being carried out after preclinical studies... -
Bionomics is developing BNC105 but will not market the drug. Instead, it is...
